Acclaro Medical Raises $23 Million in Series B Funding Led by Accelmed Partners
Deal News | May 29, 2025 | PR Newswire Cision Acclaro Medical Corporation
Acclaro Medical, a medical technology company specializing in innovative solutions for aesthetic practices, has successfully closed a $23 million Series B funding round. This funding was led by Accelmed Partners with additional participation from 3E Bioventures Capital. The investment is aimed at advancing Acclaro's groundbreaking 2910 nm fiber laser technology, which is part of its flagship products UltraClear and AuraLux. These products are designed to improve patient comfort and reduce downtime in skin rejuvenation treatments. The capital will enable Acclaro to accelerate product development, expand its team, and enter new international markets. By leveraging Accelmed’s financial and operational expertise, Acclaro aims to solidify its position as a leader in the aesthetic laser industry and to fulfill unmet needs in aesthetic practices worldwide. Acclaro Medical was co-founded by Helen Fang and Shlomo Assa and is recognized for its commitment to pioneering advancements in Total Skin Health solutions.
Sectors
- Medical Technology
- Private Equity
Geography
- United States – Acclaro Medical is based in Smithfield, Rhode Island, making the U.S. a relevant geographical area for the company's operations and expansion plans.
Industry
- Medical Technology – The article focuses on Acclaro Medical, a company in the medical technology industry, particularly in developing innovative aesthetic laser solutions.
- Private Equity – Involves Accelmed Partners leading a significant funding round to support the growth of Acclaro Medical, showcasing the role of private equity in medical technology advancements.
Financials
- $23 million – Total amount raised in Acclaro Medical's Series B funding round.
- $20 million – Investment amount contributed by Accelmed Partners.
- $3 million – Investment amount contributed by 3E Bioventures Capital.
- $630 million – Equity capital managed by Accelmed Partners overall.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Acclaro Medical | Target Company | Company | A medical technology company developing innovative laser solutions for the aesthetic industry. |
| Accelmed Partners | Leading Investment Firm | Company | A private equity firm leading the Series B funding round for Acclaro Medical. |
| 3E Bioventures Capital | Existing Investor | Company | An existing investor contributing to the Series B round for Acclaro Medical. |
| Helen Fang | CEO and Co-founder of Acclaro Medical | Person | Co-founder and CEO of Acclaro Medical, overseeing the company's growth and product development. |
| Shlomo Assa | President and Co-founder of Acclaro Medical | Person | Co-founder and President of Acclaro Medical, involved in strategic expansion efforts. |
| Daniel Cohen | Venture Partner at Accelmed | Person | Venture Partner at Accelmed, involved in the Series B funding for Acclaro Medical. |